Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/AAC.00399-20 http://scihub22266oqcxt.onion/10.1128/AAC.00399-20 32152082!7179632!32152082     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32152082.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Antimicrob+Agents+Chemother 2020 ; 64 (5): ä Nephropedia Template TP {{tp|p=32152082|t=2020. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus |pdf=|usr=}}{{32152082}} gab.com Text Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus JO: Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32152082 #FOAvip Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease 2019], or 2019-nCoV [2019 novel coronavirus]) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of infections by high-morbidity human coronaviruses, such as SARS-CoV in 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus, SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in nonhuman animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors lopinavir/ritonavir and interferon beta (LPV/RTV-IFN-beta) was shown to be effective in patients infected with SARS-CoV. LPV/RTV-IFN-beta also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-IFN-beta against MERS-CoV in a transgenic humanized mouse model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, have suggested that proinflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aims to provide a summary of therapeutic compounds that have shown potential in fighting SARS-CoV-2 infections. Twit Text FOAVip Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus ????Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32152082 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32152082 #FOAvip English Wikipedia <ref>{{Cite pmid|32152082}}</ref> Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus #MMPMID32152082 Martinez MA Antimicrob Agents Chemother 2020[Apr]; 64 (5): ä PMID32152082show ga Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease 2019], or 2019-nCoV [2019 novel coronavirus]) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of infections by high-morbidity human coronaviruses, such as SARS-CoV in 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus, SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in nonhuman animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors lopinavir/ritonavir and interferon beta (LPV/RTV-IFN-beta) was shown to be effective in patients infected with SARS-CoV. LPV/RTV-IFN-beta also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-IFN-beta against MERS-CoV in a transgenic humanized mouse model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, have suggested that proinflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aims to provide a summary of therapeutic compounds that have shown potential in fighting SARS-CoV-2 infections. |Adenosine Monophosphate/*analogs & derivatives/therapeutic use[MESH] |Alanine/*analogs & derivatives/therapeutic use[MESH] |Animals[MESH] |Antibodies, Monoclonal/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19 Serotherapy[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/*drug therapy/therapy[MESH] |Drug Combinations[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Interferon-beta/therapeutic use[MESH] |Lopinavir/*therapeutic use[MESH] |Mice, Transgenic[MESH] |Middle East Respiratory Syndrome Coronavirus/drug effects[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Ribavirin/therapeutic use[MESH] |Ritonavir/*therapeutic use[MESH] |SARS-CoV-2[MESH] |Severe acute respiratory syndrome-related coronavirus/drug effects[MESH]Compounds with Therapeutic Potential against Novel Respiratory 2019 Co(epmc).pdf DeepDyve Pubget Overpricing